122 related articles for article (PubMed ID: 16258472)
1. New therapies for mantle cell lyphoma.
Williams ME
Clin Adv Hematol Oncol; 2003 Dec; 1(12):708, 11. PubMed ID: 16258472
[No Abstract] [Full Text] [Related]
2. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
Ogura M
Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
[No Abstract] [Full Text] [Related]
3. R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma.
Lim SH; Esler WV; Periman PO; Beggs D; Zhang Y; Townsend M
Br J Haematol; 2008 Jul; 142(3):482-4. PubMed ID: 18510683
[No Abstract] [Full Text] [Related]
4. High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen.
Magni M; Di Nicola M; Carlo-Stella C; Matteucci P; Devizzi L; Tarella C; Benedetti F; Martelli M; Patti C; Parvis G; Rambaldi A; Barbui T; Gianni AM
Bone Marrow Transplant; 2009 Mar; 43(6):509-11. PubMed ID: 18955979
[No Abstract] [Full Text] [Related]
5. Treatment of mantle cell lymphoma: current approach and future directions.
Brody J; Advani R
Crit Rev Oncol Hematol; 2006 Jun; 58(3):257-65. PubMed ID: 16751087
[TBL] [Abstract][Full Text] [Related]
6. [New data prove therapeutic superiority. MabThera in follicular and mantle cell lymphoma].
Krankenpfl J; 2002; 40(5-6):161. PubMed ID: 12271501
[No Abstract] [Full Text] [Related]
7. [Mantle cell lymphoma].
Ogura M
Rinsho Ketsueki; 2001 Apr; 42(4):281-7. PubMed ID: 11400298
[No Abstract] [Full Text] [Related]
8. Mantle cell lymphoma of the iris.
Economou MA; Kopp ED; All-Ericsson C; Seregard S
Acta Ophthalmol Scand; 2007 May; 85(3):341-3. PubMed ID: 17488468
[No Abstract] [Full Text] [Related]
9. Radioimmunotherapy in mantle cell lymphoma.
Skarbnik AP; Smith MR
Best Pract Res Clin Haematol; 2012 Jun; 25(2):201-10. PubMed ID: 22687456
[TBL] [Abstract][Full Text] [Related]
10. Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?
Lenz G; Dreyling M
Nat Clin Pract Oncol; 2005 Feb; 2(2):72-3. PubMed ID: 16264875
[No Abstract] [Full Text] [Related]
11. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.
de Guibert S; Jaccard A; Bernard M; Turlure P; Bordessoule D; Lamy T
Haematologica; 2006 Mar; 91(3):425-6. PubMed ID: 16531272
[TBL] [Abstract][Full Text] [Related]
12. Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract.
Michopoulos S; Petraki K; Matsouka C; Kastritis E; Chrysanthopoulou H; Dimopoulos MA
J Clin Oncol; 2008 Mar; 26(9):1555-7. PubMed ID: 18349408
[No Abstract] [Full Text] [Related]
13. Successful treatment of focal segmental glomerulosclerosis in association with mantle cell lymphoma.
Wong CF; Mohteshamzadeh M; Arsalanizadeh B; Dutt T; Shawki H; Khine MM; Rustom R
Ren Fail; 2007; 29(3):363-6. PubMed ID: 17497453
[No Abstract] [Full Text] [Related]
14. [Maintenance therapy with rituximab].
Krankenpfl J; 2005; 43(7-10):222-4. PubMed ID: 16515293
[No Abstract] [Full Text] [Related]
15. Syngeneic transplant in mantle cell lymphoma: a rare event and review of the literature.
Engman CA; Hill JM; Meehan KR
Clin Adv Hematol Oncol; 2009 May; 7(5):321-3. PubMed ID: 19521320
[No Abstract] [Full Text] [Related]
16. Unmet needs in the treatment of mantle cell lymphoma.
Rosen ST; Link BK; Fowler NH
Clin Adv Hematol Oncol; 2013 Nov; 11(11 Suppl 18):1-19. PubMed ID: 24893041
[TBL] [Abstract][Full Text] [Related]
17. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
19. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
Evens AM; Winter JN; Hou N; Nelson BP; Rademaker A; Patton D; Singhal S; Frankfurt O; Tallman MS; Rosen ST; Mehta J; Gordon LI
Br J Haematol; 2008 Feb; 140(4):385-93. PubMed ID: 18162124
[TBL] [Abstract][Full Text] [Related]
20. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
